161 related articles for article (PubMed ID: 38572316)
21. Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
Suryawanshi RK; Taha TY; McCavitt-Malvido M; Silva I; Khalid MM; Syed AM; Chen IP; Saldhi P; Sreekumar B; Montano M; Foresythe K; Tabata T; Kumar GR; Sotomayor-Gonzalez A; Servellita V; Gliwa A; Nguyen J; Kojima N; Arellanor T; Bussanich A; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Wang Y; Ghazarian S; Davis G; Rodriguez D; Doudna J; Spraggon L; Chiu CY; Ott M
Emerg Microbes Infect; 2023 Dec; 12(2):2270071. PubMed ID: 37869789
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.
Wang Q; Guo Y; Schwanz LT; Mellis IA; Sun Y; Qu Y; Urtecho G; Valdez R; Stoneman E; Gordon A; Wang HH; Ho DD; Liu L
Emerg Microbes Infect; 2024 Dec; 13(1):2359004. PubMed ID: 38779718
[TBL] [Abstract][Full Text] [Related]
23. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
24. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
Li J; Mao H; Song W; Chen Y; Feng Y; Li J; Su L; Li X; Shi W; Wu Y; Huang C; Zhang Y; Chen K
J Med Virol; 2023 Dec; 95(12):e29306. PubMed ID: 38084772
[TBL] [Abstract][Full Text] [Related]
25. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
Xiang T; Wang J; Zheng X
Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
[TBL] [Abstract][Full Text] [Related]
26. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
[TBL] [Abstract][Full Text] [Related]
27. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.
Wang X; Jiang S; Ma W; Li X; Wei K; Xie F; Zhao C; Zhao X; Wang S; Li C; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Li J; Hu Z; Zhang W; Jiang S; Li M; Zhang Y; Wang P
Cell Host Microbe; 2024 Jan; 32(1):25-34.e5. PubMed ID: 38029742
[TBL] [Abstract][Full Text] [Related]
28. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
[TBL] [Abstract][Full Text] [Related]
29. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
[TBL] [Abstract][Full Text] [Related]
30. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
[TBL] [Abstract][Full Text] [Related]
31. Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection.
Chen Z; Li J; Zheng J; Jin Y; Zhang Y; Tang F; Li J; Cheng H; Jiang L; Wen H; Hong C; Zeng X; Huang S; Lu B; Li L; Wang Z
J Med Virol; 2023 Feb; 95(2):e28539. PubMed ID: 36719034
[TBL] [Abstract][Full Text] [Related]
32. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
[TBL] [Abstract][Full Text] [Related]
33. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
34. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
35. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
[TBL] [Abstract][Full Text] [Related]
36. An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults.
Li T; Luo D; Ning N; Wang X; Zhang L; Yang X; Li D; Sun Y; Yu W; Wei W; Wang H
Emerg Microbes Infect; 2023 Dec; 12(1):2207670. PubMed ID: 37272331
[TBL] [Abstract][Full Text] [Related]
37. Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
Zhao XJ; Liu XL; Liang YM; Zhang S; Liu T; Li LB; Jiang WG; Chen JJ; Xu Q; Lv CL; Jiang BG; Kou ZQ; Wang GL; Fang LQ
J Med Virol; 2024 May; 96(5):e29640. PubMed ID: 38699969
[TBL] [Abstract][Full Text] [Related]
38. Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections.
Ju B; Fan Q; Wang M; Liao X; Guo H; Wang H; Ge X; Liu L; Zhang Z
Nat Commun; 2022 Nov; 13(1):7120. PubMed ID: 36402756
[TBL] [Abstract][Full Text] [Related]
39. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.
Wang Q; Guo Y; Tam AR; Valdez R; Gordon A; Liu L; Ho DD
Cell Rep Med; 2023 Nov; 4(11):101258. PubMed ID: 37909042
[TBL] [Abstract][Full Text] [Related]
40. Sequential reinfection with Omicron variants elicits broader neutralizing antibody profiles in booster vaccinees and reduces the duration of viral shedding.
Wei D; Yu X; Li Y; Chen Y; Chen E; Wang Y; Yang Z; Zhang X
J Med Virol; 2023 Oct; 95(10):e29151. PubMed ID: 37805829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
